Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Allogene Therapeutics Inc
(NQ:
ALLO
)
2.740
+0.100 (+3.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Allogene Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
A Closer Look at 6 Analyst Recommendations For Allogene Therapeutics
August 08, 2024
Via
Benzinga
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
August 08, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
7 Biotech Stocks to Buy for Their Game-Changing Potential
August 08, 2024
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.
Via
InvestorPlace
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
August 07, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Analyst Ratings For Allogene Therapeutics
May 31, 2024
Via
Benzinga
Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views
May 15, 2024
Via
Benzinga
Recap: Allogene Therapeutics Q4 Earnings
March 14, 2024
Via
Benzinga
Allogene Therapeutics Earnings Preview
March 13, 2024
Via
Benzinga
Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
July 31, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
July 19, 2024
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune...
Via
Benzinga
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
July 01, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
June 20, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names
May 28, 2024
Penny stocks to buy carry a great deal of risk. However, there are a few that look interesting after due diligence.
Via
InvestorPlace
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
May 23, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 21, 2024
Via
Benzinga
Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
May 21, 2024
Via
Benzinga
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
May 15, 2024
Via
Benzinga
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
May 15, 2024
Via
Benzinga
ALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 13, 2024
ALLO stock results show that Allogene Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
May 13, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
May 13, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
May 06, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 06, 2024
Via
Benzinga
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
April 26, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
April 18, 2024
Via
Benzinga
Topics
ETFs
3 Meme Stocks to Sell and Replace With Meme Coins
April 11, 2024
For investors who want to avoid losses, sell or avoid certain meme stocks that are on the radar for potential sell-offs.
Via
InvestorPlace
Allogene Therapeutics Announces Q2 Investor Conference Participation
April 09, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
ALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023
March 14, 2024
ALLO stock results show that Allogene Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
March 14, 2024
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 14, 2024
March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.